NLRP3-IN-76
NLRP3-IN-76 is an orally active NLRP3 inhibitor. NLRP3-IN-76 inhibits the production of NO, and the mRNA levels of proinflammatory cytokines (iNOS, IL-6, IL-1β and TNFα). NLRP3-IN-76 shows anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome and NF-κB signaling pathway. NLRP3-IN-76 ameliorates DSS (HY-116282C)-induced colitis and can be used for research of inflammatory bowel diseases (IBD).
For research use only. We do not sell to patients.
- Formula: C17H14N4O4
- Molecular Weight:338.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
NLRP3-IN-76 (Compound ST12) (10 μM, 24 h) inhibits nitric oxide (NO) production (52.67%) in LPS induced RAW264.7 cells[1].
NLRP3-IN-76 (10 μM, 24 h) inhibits mRNA levels of proinflammatory cytokines in LPS-stimulated RAW264.7 cells, such as inducible NO synthase (iNOS), IL-6, IL-1β and TNF-α[1].
NLRP3-IN-76 (2.5-10 μM, 24 h) inhibits NLRP3 inflammasome activation and NF-κB signaling pathway in LPS-stimulated RAW264.7 cells [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LPS (0.1 μg/mL) induced RAW264.7 cells
-
Concentration:2.5, 10 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited the mRNA levels of inflammatory factors (iNOS, IL-6, IL-1β and TNF-α) at 10 μM.
Inhibited the mRNA levels of IL-6, IL-1β at 2.5 μM.
-
Cell Line:LPS (0.1 μg/mL) induced RAW264.7 cells
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Dose-dependently downregulated the expression of p-IκBα and p-p65 without affecting IκBα and p65.
Downregulated the expression of NLRP3.
Inhibited the expression of caspase-1, IL-18 and GSDMD.
In Vivo
NLRP3-IN-76 (100-400 mg/kg, p.o.) is well-tolerated in the C57 mice (LD50: 300 mg/kg)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:2.6 % DSS induced colitis in male C57BL/6 mice (6-7 weeks)[1]
-
Dosage:35 mg/kg
-
Administration:Intragastric gavage (i.g.), 9 days
-
Result:Increased the colon lengths (6.09 cm) compared to the DSS-induced colitis model group (4.39 cm).
Alleviated the DSS-induced reduction in crypt numbers and depletion of goblet cells.
Reduced DSS-induced CD86-positive cells.
Reduced the p-IκBα and p-p65 levels in colonic tissues.
No significant organ toxicity was observed.
Chemical Information
-
Molecular Weight 338.32
-
Formula C17H14N4O4
-
SMILES
COC1=CC=C(C2=NC(C(NNC(C3=NC=CC=C3)=O)=O)=CO2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)